Original paper
Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab
Volume: 27, Issue: 4, Pages: 821 - 826
Published: Jun 30, 2020
Abstract
Introduction Blinatumomab is a CD19/CD3 bispecific T-cell engager (BiTE) antibody that simultaneously binds CD19 on the surface of B-cells and CD3 on the surface of T-cells, resulting in tumor cell lysis. It is approved for the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and in patients with minimal residual disease after intensive induction chemotherapy. Relapse patterns after treatment with...
Paper Details
Title
Characterization of relapse patterns in patients with acute lymphoblastic leukemia treated with blinatumomab
Published Date
Jun 30, 2020
Volume
27
Issue
4
Pages
821 - 826
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History